# Shenzhen Jinshi Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-jinshi-technology-co

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.geneus-tech.com
- Total disclosed funding: $29M
- Latest round: Series B (Mar 3, 2025)
- Investors on record: 14

## About

Based in Chengdu, China and founded in 2017, Shenzhen Jinshi Technology Co., Ltd. operates as a developer of gene sequencer and reagent that is dedicated to the development of fourth-generation nanopore gene sequencers and reagents. The company's chief scientific officer and chairman of board Dr. Yaozhong Zou was graduated from Peking University, once served as senior chief scientist of Roche and Pfizer. Jinshi Technology has been evaluated as a safe production enterprise and won the first prize of BioTianfu Cup Precision Medicine Dual Innovation Competition. In March 2025, the company raised approximately CNY 100 million in series B++ funding led by new investor BIO-TOWN Capital.

Shenzhen Jinshi Technology Co., Ltd. has developed nanopore sequencer based on the technology of sequencing by synthesis, it can reduce sequencing cost, improve data quality and sequencing efficiency. The main products include Gseq500 medium-throughput gene sequencer, MK highly integrated chip, and CX01 sequencing kit. The sequencing chip MK series has 512K nanopore channels and can produce 20G of data in 10 hours when used with the Gseq500 sequencer. 

The company generates revenue by developing and providing nanopore gene sequencers and reagents.

The company will use the series B++ funding to accelerate the commercialization of the single-base nanopore sequencing (SNS) technology platform. It plans to launch the 150Gb throughput sequencing platform G-seq1K and direct RNA detection kit and supporting sequencing algorithm in Q2 2025, and the methylation direct detection kit and supporting sequencing algorithm in Q4 2025.

## Funding rounds

- Series B, Mar 3, 2025, $14M — Sichuan Venture Capital, BIO-TOWN Capital
- Series B, Mar 2, 2023 — GF Xinde Investment, Wanyuandian Fund
- Series B, Sep 29, 2021, $16M — Hong Shan, Shanghai Jianyi Private Equity Fund Management, China Growth Capital, Weidu Capital, Darun Capital, Rays Venture Capital, Potentialcap.com, Grand Mount Capital
- Series A, Jul 31, 2020 — Weidu Capital, Darun Capital
- Angel, Jan 29, 2018 — Co-Win Ventures, Zhijin Capital

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Angel
- Zhijin Capital — Angel
- Weidu Capital (https://capitalatlas.ai/funds/weidu-capital) — Series A, Series B
- Darun Capital (https://capitalatlas.ai/funds/darun-capital) — Series A, Series B
- Hong Shan — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series B
- Rays Venture Capital (https://capitalatlas.ai/funds/rays-venture-capital) — Series B
- Potentialcap.com — Series B
- Grand Mount Capital (https://capitalatlas.ai/funds/grand-mount-capital) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- Wanyuandian Fund — Series B
- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Series B
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series B